Alpha Teknova, Inc.AA

Alpha Teknova, Inc.

5.21USDR
−0.23−4.23%
At close at Mar 28, 20:05 GMT
USD
No trades
See on Supercharts

TKNO fundamentals

Key facts

Market capitalization‪278.41 M‬USD
Basic EPS (TTM)−0.58USD
Founded1996
CEOStephen Gunstream
About

Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.

Ownership
‪‪53.44 M‬‬
Closely held shares
‪‪42.85 M‬‬ (80.2%)
Free Float shares
‪‪10.58 M‬‬ (19.8%)
Closely held shares
‪‪42.85 M‬‬ (80.2%)
Free Float shares
‪‪10.58 M‬‬ (19.8%)
Capital structure
Market cap
‪‪278.41 M‬‬
Debt
‪‪30.17 M‬‬
Cash & equivalents
‪‪30.40 M‬‬
Enterprise value
‪‪278.18 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪278.41 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
7.69x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
7.69x
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪3.00‬
‪6.00‬
‪9.00‬
‪12.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−139%‬
‪−118%‬
‪−97%‬
‪−76%‬
‪−55%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−12.00 M‬‬
‪‪−6.00 M‬‬
‪0.00‬
‪‪6.00 M‬‬
‪‪12.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−10.00 M‬‬
‪‪−5.00 M‬‬
‪0.00‬
‪‪5.00 M‬‬
‪‪10.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−10.00 M‬‬
‪‪−5.00 M‬‬
‪0.00‬
‪‪5.00 M‬‬
‪‪10.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Lab Essentials
Clinical Solutions
Other
By country
Period: 2024
United States
International

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪2.50 M‬‬
‪‪5.00 M‬‬
‪‪7.50 M‬‬
‪‪10.00 M‬‬
Actual
Estimate
Earnings
Next:May 7, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.28‬
‪−0.21‬
‪−0.14‬
‪−0.07‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

TKNO does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−11.00 M‬‬
‪0.00‬
‪‪11.00 M‬‬
‪‪22.00 M‬‬
‪‪33.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪20.00 M‬‬
‪‪40.00 M‬‬
‪‪60.00 M‬‬
‪‪80.00 M‬‬
Assets
Liabilities